PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Al ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.